Rivastigmine in the Treatment of Dementia: From the Symptomatic Effect to Neuroprotection

Authors

  • Abdullayeva N. N Department of Neurological Diseases Samarkand State Medical University
  • Kasimov A. A Department of Neurological Diseases Samarkand State Medical University
  • Bozorova S. N Department of Neurological Diseases Samarkand State Medical University
  • Jumanova G. E Department of Neurological Diseases Samarkand State Medical University

Keywords:

dementia, mild cognitive impairment, treatment, rivastigmine

Abstract

Dementia is a hot topic today, largely as a result of the ageing of the population. One of the most common causes of dementia is Alzheimer's disease (AD). This disease, which is classified as a primary degenerative dementia, is characterized by a progressive decline in cognitive functions, primarily memory, and the development of behavioral disorders.

 

Downloads

Published

2023-06-30

How to Cite

N. N, A. ., A. A, K. ., S. N, B. ., & G. E , J. . (2023). Rivastigmine in the Treatment of Dementia: From the Symptomatic Effect to Neuroprotection. Scholastic: Journal of Natural and Medical Education, 2(6), 266–273. Retrieved from https://univerpubl.com/index.php/scholastic/article/view/2253

Issue

Vol. 2 No. 6 (2023): Scholastic: Journal of Natural and Medical Education

Section

Articles